Recro Pharma, Inc. (REPH) Rating Lowered to Hold at Zacks Investment Research

Recro Pharma, Inc. (NASDAQ:REPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

REPH has been the topic of several other reports. Roth Capital set a $20.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies set a $11.00 price target on Recro Pharma and gave the stock a “buy” rating in a report on Tuesday, July 25th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $12.88.

Shares of Recro Pharma (REPH) remained flat at $$8.77 during mid-day trading on Thursday. 61,285 shares of the company were exchanged, compared to its average volume of 82,358. Recro Pharma has a one year low of $5.81 and a one year high of $10.17. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59.

COPYRIGHT VIOLATION WARNING: “Recro Pharma, Inc. (REPH) Rating Lowered to Hold at Zacks Investment Research” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/18/recro-pharma-inc-reph-rating-lowered-to-hold-at-zacks-investment-research.html.

A number of large investors have recently made changes to their positions in REPH. OxFORD Asset Management LLP grew its stake in Recro Pharma by 364.3% in the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock worth $1,430,000 after purchasing an additional 159,619 shares in the last quarter. State Street Corp bought a new position in Recro Pharma in the second quarter worth approximately $1,047,000. Northern Trust Corp grew its stake in Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after purchasing an additional 144,676 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Recro Pharma by 787.4% in the second quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock worth $911,000 after purchasing an additional 114,960 shares in the last quarter. Finally, JT Stratford LLC bought a new position in Recro Pharma in the second quarter worth approximately $704,000. 65.27% of the stock is currently owned by institutional investors.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

What are top analysts saying about Recro Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Recro Pharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit